Blue Light Phototherapy Research Articles

Prospective Clinical Study: Full-Body Blue Irradiation in the Treatment of Atopic Dermatitis.

Ultraviolet-free (UV-free) blue light phototherapy has emerged as a promising option due to its reported efficacy and minimal adverse effects. This study aims to evaluate the effectiveness of full-body blue light irradiation in both adult and pediatric patients with atopic dermatitis (AD), assessing its impact on skin condition and mood regulation by investigating serum concentrations of serotonin and kynurenine pathway metabolites. 20 patients (age 9-45) with moderate and severe AD were included in the study. Treatment consisted of 10 irradiations with Full Body Blue device (453nm). Serum concentrations of serotonin, quinolinic acid, kynurenic acid, tryptophan, and kynurenine were measured before and after irradiations. After 10 sessions of full blue light therapy (453nm) statistically significant improvements were observed in Eczema Area Severity Index (EASI 13.16 vs. 8.65; p = 0.00016), SCORing Atopic Dermatitis (SCORAD 44.99 vs. 23.73; p < 0.00001), Visual Analogue Scale (VAS 6.53 vs. 3.95; p = 0.00251), 10-item pruritus severity scale (13.32 vs. 7.05; p < 0.00001). Moreover, statistically significant decrease in Dermatology Life Quality Index (DLQI) was noted (14.37 vs. 7.42; p = 0.00351). Additionally, increase in the serum concentration of serotonin was observed after completing 10 irradiation sessions (median 139.77mg/ml vs. 274.92mg/ml; p < 0.00001). Blue light may be a promising and safe treatment in patients with AD. It might also positively influence mood. Further investigations are needed to confirm those findings. ClinicalTrials.gov identifier, NCT06516783.

A prospective, randomized, controlled, double-blind, multi-center study to evaluate the efficacy and safety of a blue light device for the treatment of chronic back pain.

Chronic back pain is one of the most prevalent conditions and has a large socio-economic impact. The lack of routine use of non-pharmacological options and issues associated with pharmacological treatments underscore high unmet needs in the treatment of back pain. Although blue light phototherapy has proven efficacy in dermatology, limited information is available about its use in back pain. In this proof-of-concept, randomized controlled trial, a pain relief patch (PRP) delivered blue light at the site of back pain for 30 min during five treatment sessions. The comparator device delivered green light for 5 s but was worn for 30 min. A follow-up visit took place after the last treatment. The primary objective was to demonstrate the superiority of treatment by PRP, compared to the control device, in reducing pain intensity at the end of the treatment period. The post-treatment visual analog scale (VAS) pain intensity score for each group was calculated across the five treatment sessions and compared to the baseline. Secondary objectives included the disability score (Roland-Morris Disability Questionnaire) and safety. The full analysis set included 171 patients. A statistically significant reduction in pain intensity occurred after the use of PRP (p < 0.02), but the study did not meet its primary objective of a superiority trial aimed at demonstrating a 0.6 cm difference in favor of PRP on the VAS scale. There was no significant change in the disability scores. Subgroup analyses were performed to identify the treatment response by patient characteristics such as pain intensity at baseline and skin type. As expected, safety data showed erythema and skin discoloration in the PRP group but not in the control group. This trial had multiple limitations that need to be addressed in future research. Although the primary objective was not achieved, this proof-of-concept study provides important efficacy and safety data in relation to the use of blue light in the treatment of chronic back pain and key insights that may support further research on similar devices. ClinicalTrials.gov, identifier NCT01528332.

Treatment of infected wounds by using antimicrobial blue light phototherapy

Treatment of infected wounds by using antimicrobial blue light phototherapy

Probiotics' effects on gut microbiota in jaundiced neonates: a randomized controlled trial protocol.

Recent evidence suggests that blue-light phototherapy impacts gut microbiota composition in jaundiced newborns, leading to disturbances closely related to the therapy's side effects. As a result, gut microbiota may serve as a potential intervention target to mitigate these side effects. In this study, we aim to examine the effects of AB-GG (Lactobacillus rhamnosus LGG), Bb-12 (Bifidobacterium animalis Bb-12) and M-16V (Bifidobacterium breve M-16V) and their combination on the intestinal microbiota, metabolomics and phototherapy-related side effects in neonates with jaundice. A total of 100 jaundiced newborns aged two weeks or younger will be included in this randomized, single-blind (the parents knew, but the neonatologists did not know), single-center controlled trial to receive either 109 colony-forming units of AB-GG, Bb-12, M-16V, a combination of the three probiotics with blue-light phototherapy, or blue-light phototherapy alone. The experimental group will be treated with oral probiotics once daily for 30 days, while the control group will receive only blue-light phototherapy. The follow-up duration will last 30 days. The primary outcomes include changes in gut microbiota, metabolomics, and the incidence of phototherapy side effects, assessed after each phototherapy session, as well as on days 10, 20, and 30. The study protocol has been approved by the Ethics Committee of our institution. The findings of this trial will be submitted to a peer-reviewed pediatric journal. Its abstracts will be submitted to relevant national and international conferences. http://www.chictr.org.cn/index.aspx, identifer (ChiCTR2000036013).

The effect of Lactobacillus acidophilus,Streptococcus thermophilus, and Bifidobacterium longum probiotics on bilirubin levels of neonates with hyperbilirubinemia

Hyperbilirubinemia, a common illness in newborns that can lead to hospital readmission, has been treated with blue light phototherapy. This treatment, either on its own or in combination with probiotics, has shown fast and significant decreases in bilirubin levels in the blood, helping to speed up the fading of jaundice. This study aims to examine the effects of combining phototherapy with probiotics containing Lactobacillus acidophilus, Streptococcus thermophilus, and Bifidobacterium longum on newborns with hyperbilirubinemia. The study was conducted at Sultan Agung Islamic Hospital (RSI Sultan Agung), Semarang, using a randomized controlled trial design. It included newborns who were hospitalized between August and November 2022. The control group was administered phototherapy, whereas the treatment group received both phototherapy and probiotics for 7 days. SPSS software analysis demonstrated a statistically significant reduction in average levels of total and indirect bilirubin in the intervention group (6.50 mg/dl and 7.20 mg/dl) compared to the control group (6.70 mg/dl and 7.48 mg/dl). These findings highlight the potential effectiveness of the combined approach in controlling hyperbilirubinemia. The study proposes using probiotics as a safe additional treatment for neonatal hyperbilirubinemia, showing that it is well-tolerated and safe for the participants. Although the combination of probiotics and phototherapy did not show a significant difference compared to phototherapy alone, it did result in a faster average decrease in hyperbilirubinemia. This could reduce the necessity for hospital readmissions to manage this condition. The findings underscore the potential of probiotics as a helpful supplement to established treatment methods for newborn hyperbilirubinemia.

Impact of Light Emitting Diode Phototherapy in Full-Term Neonates with Hyperbilirubinemia

Abstract Background: To study the difference in serum total calcium levels during phototherapy with light-emitting diodes (LEDs) in full-term neonates with hyperbilirubinemia. Materials and Methods: In this prospective observational study, 74 term neonates with hyperbilirubinemia who were admitted for phototherapy using LEDs devices were examined. The research was carried out in a tertiary care facility. Before and after the phototherapy treatment, total serum bilirubin levels as well as total serum calcium levels were measured and compared. The symptoms observed with hypocalcemia, such as drowsiness irritability/excitability, lethargy, and convulsions, were also evaluated in full-term neonates during this study. Results: After treatment, the total serum calcium level decreased significantly (P &lt; 0.001) compared to the pretreatment level. Around 5% of the term neonates who participated in the study had hypocalcemia, where the serum calcium level is defined that is lower than 8 mg/dL in term neonates. Conclusions: In the context of the treatment of neonatal jaundice in full-term neonates, LED phototherapy, which is analogous to traditional blue and white light phototherapy, also has hypocalcemia as one of its potential side effects. During their treatment with light-emitting diode phototherapy, we advise checking up on these full-term neonates for signs of hypocalcemia.

A Case Report on Congenital Biliary Atresia with Ventricular Septal Defect

Biliary atresia, an obstructive cholangiopathy with an idiopathic etiology, is a congenital disorder that eventually destroys liver parenchyma. In some circumstances, it is associated with other abnormalities such as congenital heart diseases, intestinal, and spleen anomalies. Diagnosis of biliary atresia is based on clinical manifestations and specific diagnostic tests. Prolonged pathological jaundice is a critically important sign in newborns that needs to be recognized early in order to reduce the chances of further complications. The mainstay of treatment is the Kasai procedure (portoenterostomy), and it is eighty percent successful if performed before or within the first two months of life.Here, we report a case of a two-month-old baby who had biliary atresia with a ventricular septal defect (VSD). The baby had a prolonged history of jaundice, pruritus, yellow-colored urine, and pale stools. He was initially brought to a local clinic for his jaundice, where pharmacological treatment was commenced. However, the symptoms persisted, and he was referred to a hospital where he was placed under blue light phototherapy with no marked improvement in his symptoms. For a definite diagnosis and treatment, he was then referred to a multispecialty hospital where diagnostic tests were ordered. The HIDA scan showed no uptake of contrast in the bile ducts and gallbladder, which is suggestive of congenital biliary atresia. An intraoperative cholangiogram showed a definite diagnosis of biliary atresia, which was performed, and the Kasai procedure was done successfully. All his family members were healthy with no history of congenital disease.The essential outcome in this case is to consider biliary atresia as a cause of prolonged jaundice in infants, and occasionally it is associated with other congenital anomalies. The diagnosis and treatment should be urgent in order to prevent complications.

Gyermekbőrgyógyászati kutatások a szegedi Bőrgyógyászati és Allergológiai Klinikán 2004-2023 között

The authors present their most relevant clinical investigations in the field of paediatric dermatology, performed in the Department of Dermatology and Allergology, University of Szeged, between 2004-2023. In their epidemiological surveys, wide spectrum of dermatological manifestations and disorders were consecutively recorded both in healthy, mature newborn infants and in premature infants referred to the Neonatal Intensive Care Unit. Different neonatal, maternal, diagnostic and other factors behind the skin symptoms were also investigated in detail. In their twin-studies, the authors investigated the effect of neonatal blue-light phototherapy on cutaneous and uveal naevus development, and the roles of different environmental and constitutional factors on naevus formation were also analysed in identical and non-identical twin pairs. The success of the treatment of chronic dermatological diseases considerably depends on the patient’s compliance. The main objectives of their study were to investigate the therapeutic compliance of patients diagnosed with acne vulgaris, in order to explore factors behind low compliance.

A case of verruca plana juvenile responding to blue light phototherapy

A case of verruca plana juvenile responding to blue light phototherapy

Effects of comfort care combined with blue-light phototherapy on neonatal jaundice and total bilirubin and high-sensitivity C-reactive protein levels

In order to explore the effects of comfort care combined with blue-light phototherapy on neonatal jaundice and total bilirubin (TBIL) and high-sensitivity C-reactive protein (hsCRP) levels, this study selected 100 neonates as research objects. Those 100 neonates were diagnosed with neonatal jaundice in a designated hospital of this study from December 2020 to December 2021, and randomly divided into observation group and control group with 50 cases in each group. The neonates in control group were given blue-light phototherapy, while the neonates in observation group were given comfort care combined with blue-light phototherapy. Before and after the treatment, the neonates in the two groups were evaluated for their quiet sleep time, the number of crying, decrease in jaundice, weight gain, and TBIL and hs-CRP levels, and compared those indicators for follow-up analysis. The results of this study show that the total effective rate was 96.0 % (48/50) in the observation group and 82.0 % (41/50) in the control group, with statistically significant difference between the two groups (P < 0.05); the indexes of the neonates’ jaundice decline [(4.41 ± 0.71) μmol/l] of the observation group were significantly better than the neonates’ jaundice decline [(3.32 ± 0.68) μmol/l] of the control group (P < 0.05); before treatment, there was no statistically significant difference in the levels of TBIL [(304.12 ± 27.63) μmol/l] and Hs-CRP [(8.01 ± 2.29) mg/L] of the observation group between the levels of TBIL [(304.08 ± 27.58) μmol/l] and Hs-CRP [(8.03 ± 2.41) mg/L] of the control group (P > 0.05); after treatment, the TBIL level [(99.27 ± 11.35) μmol/l] and hs-CRP level [(1.18 ± 0.32) μmol/l] of the observation group and the TBIL level [(123.25 ± 19.43) μmol/l] and hs-CRP level [(1.62 ± 0.45) μmol/l] of the control group were both lower than those before treatment, while the reduction degree of those in the observation group was better than that of the control group with statistically significant difference (P < 0.05). Therefore, the comfort care combined with blue-light phototherapy can achieve more ideal treatment effects than that of single use of blue-light phototherapy, which proves that the two treatment methods have certain synergy and provides a new potential technology for the prevention and treatment of neonatal jaundice.

Assessment of Blue Light Phototherapy for Grover Disease

This nonrandomized clinical trial assesses treatment of patients diagnosed with Grover disease with blue light phytotherapy for several weeks.

Photodegradation kinetics for bilirubin sensing: New solutions for old problems

Blood bilirubin levels monitoring is essential for the management of liver disease and neonatal hyperbilirubinemia. Whilst highly accurate, the existing bilirubin measurement techniques do not lend themselves to point-of-care (PoC) applications. To address this challenge, PoC devices using optical methods (mainly transcutaneous technique), have been demonstrated for bilirubin levels determination. Beyond its distinct absorption features used for optical measurements, bilirubin is known for its unique property of a non-catalytic degradation under blue light illumination. This is indeed the basis of blue light phototherapy used to treat or alleviate neonatal jaundice. This work investigates the feasibility of measuring bilirubin concentration using both multi-wavelength (MWL) and photodegradation kinetics approaches. Multi wavelength approach was investigated by correlating the optical responses with the concentration of bilirubin. The degradation approach was investigated by assessing the changes in bilirubin's spectrophotometric characteristics induced by blue light (470 nm) irradiation as a function of optical energy density (up to 3 J/cm2). The solid-state full-range spectroscopy (absorbance, reflectance, photoluminescence, and Raman) and a PoC testing on a system-on-chip are used and a new kinetic model describing the degradation reaction is proposed. Results show that the optical responses and photodegradation features correlated well with bilirubin concentration with R-square greater than 0.9. Additionally, the techniques' performance was examined using the merits of accuracy, precision, sensitivity, and specificity parameters (all are greater than 90%). Our analyses suggest that the method is sufficiently enough to provide reliable indications of bilirubin levels. The proposed technique may offer a portable, miniaturized, and facile mean for in-vitro and in-vivo bilirubin monitoring and estimation.

Highlighting nuances of blue light phototherapy: Mechanisms and safety considerations.

The efficacy of blue light therapy in dermatology relies on numerous clinical studies. The safety remains a topic of controversy, where potentially deleterious effects were derived from in vitro rather than in vivo experiments. The objectives of this work were (1) to highlight the nuances behind "colors" of blue light, light propagation in tissue and the plurality of modes of action; and (2) to rigorously analyze studies on humans reporting both clinical and histological data from skin biopsies with focus on DNA damage, proliferation, apoptosis, oxidative stress, impact on collagen, elastin, immune cells, and pigmentation. We conclude that blue light therapy is safe for human skin. It induces intriguing skin pigmentation, in part mediated by photoreceptor Opsin-3, which might have a photoprotective effect against ultraviolet irradiation. Future research needs to unravel photochemical reactions and the most effective and safe parameters of blue light in dermatology.

284 A single-arm, prospective clinical study of blue light phototherapy as a novel treatment for Grover’s Disease and psoriasis vulgaris

Unlike ultraviolet radiation, blue light (380 nm to 500 nm) is non-ionizing representing a potentially safer and more accessible phototherapeutic modality. We investigated the feasibility, tolerability, and early efficacy of whole-body blue light for the treatment of psoriasis vulgaris and Grover’s disease in a single-arm, prospective, open-label clinical study. A total of 11 patients with Grover’s disease (mean baseline lesion count 27.4) and 9 patients with psoriasis (mean baseline Psoriasis Area and Severity Index (PASI) 6.1) completed a 2-week washout of all topical and systemic therapies and subsequently underwent whole body blue light phototherapy treatment for 15 sequential treatments over five weeks for 18 minutes using the DUSA BLU-U device.

Method for Designing and Characterizing Phototherapy Shields

Optimal shield properties and design are of vital importance for preventing adverse effects of light-based clinical procedures. The goal of this study was to select the most appropriate materials for a two-layer phototherapy shield. Four biocompatible fabrics, to be utilized as the layer contacting patients’ skin, and two reflective materials, to be utilized as the layer facing the light source, were investigated. The optical properties of the four biocompatible fabrics and transmittance of the two reflective materials were determined in the 400–500 nm range. Absorption coefficient, scattering coefficient, and anisotropy factors of biocompatible fabrics were determined using integrating sphere spectrophotometry and an inverse Monte Carlo method. Fabric and reflective materials that exhibited highest attenuation of the blue light were selected to assemble a two-layer composite prototype. Prototypes were exposed to blue light emitted from a clinical source to ensure negligible temperature increase under clinically relevant exposure conditions. A protype blue-light phototherapy shield was made from two test materials, both of which provide sufficient light attenuation to provide patient protection. The testing method employed in this study may prove valuable for designing protective gear for a range of clinical procedures .

Effect of Light-Emitting Diode Phototherapy on Serum Calcium Levels in Neonates With Jaundice.

Background: To assess the change in serum total calcium levels during light-emitting diode phototherapy treatment for jaundice in term neonates.Methods: A prospective observational study was done on 104 term neonates with hyperbilirubinemia in a tertiary care center to investigate the effects of phototherapy using a light-emitting diode device. The total serum bilirubin along with total calcium levels was measured at the start and at the end of phototherapy. Additionally, all the newborns enrolled in the study were evaluated for hypocalcaemia-related symptoms such as jitteriness, irritability/excitability, lethargy, and convulsions.Results: A significant lowering of posttreatment total calcium level compared to that of pretreatment level (p<0.001) was found in our study. Hypocalcemia (serum calcium <8 mg/dL in term neonates) was found in 12.5% of the study subjects.Conclusions: In the treatment of neonatal jaundice, similar to conventional blue and white light phototherapy, light-emitting diode phototherapy also has hypocalcemia as an adverse effect. We recommend monitoring these babies for hypocalcemia during light-emitting diode phototherapy.

The facilitating effect of blue light on the antifungal agent susceptibilities of passaged conidia from the ocular-derived Fusarium solani species complex.

The eye is a light-receiving organ and has anatomical advantages to accept phototherapy. Fungi colonizing on the eyes, which cause ocular mycoses, are affected by daily blue light and could easily accept additional light irritation. Ocular mycoses are recalcitrant and blindness-causing eye diseases, and antifungal agent treatments are insufficient. Our team previously found that blue light could inhibit Fusarium solani hyphal growth but promote conidiation. Here, we investigated the antifungal susceptibilities and biological characteristics of the passaged conidia. Twelve Fusarium solani strains (11 ocular-derived strains and 1 standard laboratory strain) were inoculated under blue light (0.5 mW/cm2) and darkness conditions, respectively, to obtain the passaged conidia of blue light group (n = 12) and darkness group (n = 12). Two groups were tested to determine the growth abilities and in vitro antifungal susceptibilities to five antifungal drugs (voriconazole (VRC), amphotericin B (AMB), terbinafine (TRB), caspofungin (CAS), and 5-flucytosine (5FC)), which were examined by microscopy for morphological observation and spectrophotometry for turbidity analysis. The results showed that blue light group passaged conidia were more sensitive to antifungal drugs (AMB, VRC, TRB, and CAS) compared to darkness group. The MIC50 of VRC significantly decreased after blue light treatment (P < 0.05). The fungal inhibition rate significantly increased for VRC, AMB, and TRB in the low concentration range (P < 0.05 or P < 0.01). Blue light did not affect germination or hyphal extension of passaged conidia. These results suggested that blue light could facilitate fungal inhibition effect of AMB, VRC, TRB, and CAS and may improve the therapeutic efficiency in VRC and AMB clinical applications. Blue light phototherapy may provide a new adjuvant approach for the treatment of ocular mycosis.

Effects of Different Types of Phototherapy Units on Neonatal Jaundice: A Cross-sectional Study

Introduction: Phototherapy is the mainstay of treatment of neonates who develop significant jaundice. Light-emitting diode and compact florescent lamp phototherapy units are the newer devices in the management of neonatal hyperbilirubinaemia. The advantage of light-emitting diode phototherapy includes portability, energy efficiency, less heat production, and durability. Blue and white phototherapy devices are more economical but generate more heat leading to hyperthermia and dehydration more often. Aim: To determine the efficacy and side effects of three modes of phototherapy units viz conventional blue and white light phototherapy, Compact Fluorescent Lamp (CFL) phototherapy, and Light-emitting Diode (LED) phototherapy on neonates having jaundice. Materials and Methods: This cross-sectional study was conducted in Department of Paediatrics at SRM Medical college Hospital and Research Centre (tertiary care teaching hospital), Kattankulathur, Tamil Nadu, India, from February 2021 to January 2022. A total of 150 neonates with hyperbilirubinaemia in the phototherapy range, American Academy of Paediatrics (AAP), were included in this study. Study subjects were divided into three groups of 50 neonates each to receive phototherapy using one of the three phototherapy devices, i.e., Blue and white light, CFL, LED phototherapy groups. Data of serum bilirubin levels were recorded at the beginning and end of phototherapy. The number of babies who required exchange transfusion and other clinical side effects among the study groups was recorded. Descriptive statistics were reported as Mean±SD for continuous variables, frequencies (percentage) for categorical variables. The One-way Analysis of Variance (ANOVA) test was used to determine the statistically significant differences between the means of three independent groups. Results: All the three type of phototherapy units generated statistically non significant mean flux (p-value=0.754). Mean difference (from the baseline bilirubin) at end of phototherapy for blue and white light group was 5.77±1.72 mg%, for CFL group was 5.48±1.32 mg%, and for LED group was 6.34±1.48 mg%. The difference was statistically significant in all three groups (p-value=&lt;0.001). The reduction in serum bilirubin at the end of phototherapy was lesser in CFL group compared to blue and white light group and LED group. Conclusion: Light-emitting diode and blue and white light phototherapy units are more effective than compact fluorescent lamp phototherapy in treating neonatal hyperbilirubinaemia.

Blue-light treatment reduces spontaneous and evoked pain in a human experimental pain model.

Chronic pain is a frequent severe disease and often associated with anxiety, depression, insomnia, disability, and reduced quality of life. This maladaptive condition is further characterized by sensory loss, hyperalgesia, and allodynia. Blue light has been hypothesized to modulate sensory neurons and thereby influence nociception. Here, we compared the effects of blue light vs red light and thermal control on pain sensation in a human experimental pain model. Pain, hyperalgesia, and allodynia were induced in 30 healthy volunteers through high-density transcutaneous electrical stimulation. Subsequently, blue light, red light, or thermal control treatment was applied in a cross-over design. The nonvisual effects of the respective light treatments were examined using a well-established quantitative sensory testing protocol. Somatosensory parameters as well as pain intensity and quality were scored. Blue light substantially reduced spontaneous pain as assessed by numeric rating scale pain scoring. Similarly, pain quality was significantly altered as assessed by the German counterpart of the McGill Pain Questionnaire. Furthermore, blue light showed antihyperalgesic, antiallodynic, and antihypesthesic effects in contrast to red light or thermal control treatment. Blue-light phototherapy ameliorates pain intensity and quality in a human experimental pain model and reveals antihyperalgesic, antiallodynic, and antihypesthesic effects. Therefore, blue-light phototherapy may be a novel approach to treat pain in multiple conditions.

New Insights Into Blue Light Phototherapy in Experimental Trypanosoma cruzi Infection.

The search for an effective etiologic treatment to eliminate Trypanosoma cruzi, the causative agent of Chagas disease, has continued for decades and yielded controversial results. In the 1970s, nifurtimox and benznidazole were introduced for clinical assessment, but factors such as parasite resistance, high cellular toxicity, and efficacy in acute and chronic phases of the infection have been debated even today. This study proposes an innovative strategy to support the controlling of the T. cruzi using blue light phototherapy or blue light-emitting diode (LED) intervention. In in vitro assays, axenic cultures of Y and CL strains of T. cruzi were exposed to 460 nm and 40 µW/cm2 of blue light for 5 days (6 h/day), and parasite replication was evaluated daily. For in vivo experiments, C57BL6 mice were infected with the Y strain of T. cruzi and exposed to 460 nm and 7 µW/cm2 of blue light for 9 days (12 h/day). Parasite count in the blood and cardiac tissue was determined, and plasma interleukin (IL-6), tumoral necrosis factor (TNF), chemokine ligand 2 (CCL2), and IL-10 levels and the morphometry of the cardiac tissue were evaluated. Blue light induced a 50% reduction in T. cruzi (epimastigote forms) replication in vitro after 5 days of exposure. This blue light-mediated parasite control was also observed by the T. cruzi reduction in the blood (trypomastigote forms) and in the cardiac tissue (parasite DNA and amastigote nests) of infected mice. Phototherapy reduced plasma IL-6, TNF and IL-10, but not CCL2, levels in infected animals. This non-chemical therapy reduced the volume density of the heart stroma in the cardiac connective tissue but did not ameliorate the mouse myocarditis, maintaining a predominance of pericellular and perivascular mononuclear inflammatory infiltration with an increase in polymorphonuclear cells. Together, these data highlight, for the first time, the use of blue light therapy to control circulating and tissue forms of T. cruzi. Further investigation would demonstrate the application of this promising and potential complementary strategy for the treatment of Chagas disease.